What Corvert Treats: Main Uses and Benefits

Corvert is generally used for the acute management of specific, fast, and irregular heart rhythms, notably Atrial Fibrillation and Atrial Flutter. This medication is applied across therapeutic domains where additional symptomatic support is needed to address conditions presenting with acute episodes and heightened physiological activity. The drug is utilized for the conversion of these acute, recent-onset arrhythmias to normal sinus rhythm.

This intervention contributes to easing the overall symptom load by supporting the prompt conversion to a normal sinus rhythm (NSR). This is commonly used in clinical settings that involve acute or unstable symptom patterns, such as the controlled setting of pharmacological cardioversion. The medication is relevant when supportive symptom management is appropriate, and may assist with maintaining functional stability when symptoms are more noticeable, including in scenarios like arrhythmias occurring post-cardiac surgery.

“This medication is primarily relevant for addressing acute electrical instability that disrupts the heart's functional stability.”

Quick Fact: Relief for Acute Arrhythmias
Used for managing: Atrial Fibrillation and Atrial Flutter of recent onset.
Key Benefit: Supports prompt conversion to normal sinus rhythm.
Typical Context: Applied in hospital settings for pharmacological cardioversion.

Regulatory References

1. NIH National Library of Medicine

Who Can and Cannot Use Corvert?

Eligibility for using Corvert (ibutilide fumarate) is strictly determined by official regulatory documents, which define specific populations that are permitted, restricted, or absolutely prohibited from treatment.

---

Contraindications (Must Not Use)

• Patients with a known hypersensitivity to ibutilide or any product components.
• Patients with a history of polymorphic ventricular tachycardia (VT), including documented Torsades de Pointes.

---

Population Restrictions and Conditional Use

Population Group	Regulatory Status
Pediatric Patients (< 18)	Safety and effectiveness have not been established.
Adults	Established population for use.
Geriatric Patients (65+)	Use requires caution due to potential decreased organ function.
Pregnancy	Restricted Use; administered only if clinical benefit outweighs potential fetal risk.
Nursing Mothers	Not recommended; breastfeeding should be discouraged.
Electrolyte Deficiencies	Conditional Use; Hypokalemia or Hypomagnesemia must be corrected before administration.
Organ Impairment	No dosage adjustment necessary for renal or hepatic impairment.

Eligibility is limited to adults with the labeled indication, and use is restricted in the presence of certain cardiovascular risk factors like a prolonged QTc interval (> 440 msec) or history of Congestive Heart Failure.

Interactions with other medicines and products

Corvert (Ibutilide fumarate) interaction patterns are defined primarily by Pharmacodynamic Reinforcement due to its effect on the heart's electrical cycle, specifically the prolongation of the QT interval. Official regulatory documentation notes that no specific pharmacokinetic studies were conducted to investigate enzyme or transporter-mediated interactions.

Restricted and Prohibited Combinations

Co-administration is officially restricted or prohibited with medicinal products that share the effect of QTc prolongation, as this increases the potential for the serious arrhythmia Torsades de Pointes. This includes:

• Class Ia and other Class III Antiarrhythmic Agents: Agents such as quinidine, procainamide, and sotalol are formally restricted.
• Other QTc-Prolonging Drugs: The interaction risk is noted with substances like phenothiazines and tricyclic or tetracyclic antidepressants.

Administration Timing and Context

Official labeling enforces strict timing rules for highly restricted combinations:

• Timing Separation: Class I or other Class III antiarrhythmic agents must not be given concomitantly with Corvert or administered within 4 hours post-infusion.
• Electrolyte Context: The proarrhythmic risk associated with these pharmacodynamic interactions is noted to be amplified in the presence of hypokalemia (low potassium) or hypomagnesemia (low magnesium).

Conversely, co-administration of Digoxin, Calcium Channel Blockers, and Beta Blockers did not affect the safety or efficacy of Corvert in clinical trials, according to official prescribing information.

How Corvert Works: The Mechanism of Action

Corvert (ibutilide) influences the electrical systems within the heart, primarily by delaying the tissue's electrical recovery time. This action is achieved through a dual mechanism affecting the cell's ion channels.

First, ibutilide acts as an inhibitor of the rapid component of the delayed rectifier potassium current ( I Kr). This I Kr blockade reduces the outward flow of positive charge (potassium ions) that normally drives the cell toward electrical reset (repolarization). Second, the drug modulates or activates a slow inward sodium current ( I Na), which introduces a persistent inward positive charge.

The net result of this dual interaction is the extension of the Action Potential Duration (APD). The subsequent physiological consequence is a prolongation of the Effective Refractory Period (ERP) across the heart muscle. This extended period of electrical unresponsiveness contributes to a functional interruption in the electrical circuit, influencing the tissue's ability to conduct a new impulse. This mechanism is subject to reverse use dependence, meaning the magnitude of the electrical delay is greater at slower heart rates.

Administration of Corvert (Ibutilide Fumarate)

Corvert is administered strictly as an intravenous (IV) infusion by healthcare professionals in a setting equipped for continuous cardiac monitoring and the management of ventricular arrhythmias. The dosage is determined by patient weight and the infusion must be delivered over a fixed time period.

Dosing and Scheduling

The full recommended dose is given as an initial infusion, and a second, equal-strength infusion may be administered only if the target arrhythmia has not terminated within 10 minutes after the completion of the first dose.

Patient Weight	Initial Infusion (Over 10 Minutes)	Second Infusion Rule
60 kg (132 lb) or more	1 mg ibutilide fumarate (One vial)	May be repeated once 10 minutes after first infusion ends.
Less than 60 kg (132 lb)	0.01 mg/kg ibutilide fumarate	May be repeated once 10 minutes after first infusion ends.

Preparation and Procedure

Corvert injection may be administered undiluted or diluted in 50 mL of either 0.9% Sodium Chloride Injection or 5% Dextrose Injection. The solution must be visually inspected for particulate matter or discoloration prior to administration. The infusion must be stopped immediately if the arrhythmia terminates or if the patient develops sustained or non-sustained ventricular tachycardia, or marked QT/QTc interval prolongation.

Following the final infusion, patients require continuous electrocardiographic (ECG) monitoring for a minimum of 4 hours or until the QTc interval has returned to its baseline value.

Corvert: Recent Clinical Evidence

Corvert (dofetilide) is a Class III antiarrhythmic agent used to convert atrial fibrillation or flutter to a normal heart rhythm and to help maintain that rhythm. Research into this medication has primarily focused on establishing its therapeutic profile, its use in different patient populations, and understanding its cardiac risks.

---

Core Research Findings (Phase III)

• Chronic Arrhythmia Conversion: Studies investigated the effectiveness of the drug in restoring normal sinus rhythm in patients with highly symptomatic atrial fibrillation or atrial flutter. In one key trial, 32% of participants receiving the 500 mcg twice-daily dose converted to sinus rhythm over three days, compared to 1% of those receiving a placebo.
• Rhythm Maintenance: Research examined the use of the drug in maintaining normal heart rhythm over the long term. One analysis indicated that after six months, 71% of patients who had converted to sinus rhythm and received the study drug remained in a normal rhythm, compared to 26% of the placebo group.
• Safety in Structural Heart Disease: The DIAMOND studies, which involved patients with heart failure or recent myocardial infarction, investigated the safety of dofetilide use in these high-risk groups. The research showed that the drug did not increase overall mortality in patients with left ventricular dysfunction or recent heart attack.

---

Cardiac Risk Monitoring

• Risk of Torsades de Pointes (TdP): All research confirms that dofetilide can prolong the QT interval, which carries a risk of TdP, a serious type of ventricular arrhythmia. The highest incidence of this proarrhythmic effect is typically observed in the first three days after starting the medication.
• Risk Factors: Clinical data suggest several factors may be associated with an increased risk of TdP, including female sex, reduced kidney function (which affects drug clearance), and the presence of severe heart failure symptoms (NYHA Class III or IV).

Key Studies & References Dofetilide (Tikosyn) - Clinical information, dosing, and safety (StatPearls - NCBI Bookshelf)

Common questions about Corvert (FAQ)

Q: How quickly does Corvert start working after it is administered?

A: Corvert is intended to be a rapid-acting medication for acute rhythm conversion. Official administration guidelines note that healthcare professionals assess the patient for a second dose about 10 minutes after the first infusion is complete. Clinical studies indicate that for many patients who successfully convert, the change occurred within 30 minutes of the start of administration.

Q: How long do the effects of Corvert typically last in the body?

A: Corvert is an acute, short-term medication not intended for long-term use. The active substance, ibutilide, has an average half-life of approximately 6 hours. Due to the risk of serious side effects, continuous heart monitoring is required for at least 4 hours following the final infusion to ensure the heart's electrical recovery time has normalized.

Q: What happens if a patient has kidney problems and is given Corvert?

A: Official prescribing information states that no change in dose is required for patients with pre-existing kidney impairment. Regulatory information advises caution in this population, as clinical data suggests that reduced kidney function is a factor associated with an increased risk of a serious heart rhythm side effect.

Q: Can Corvert be used in older patients (seniors)?

A: Corvert is established for adult use, but regulatory documents indicate caution for use in patients 65 and older. This precaution is often due to the higher frequency of potentially reduced organ function in this age group. Clinical data also suggest that age over 65 is one factor associated with an increased risk of proarrhythmia (the risk of causing a new heart rhythm problem).

Q: Why is close monitoring required when a patient receives Corvert?

A: Continuous heart monitoring is mandated by a regulatory Boxed Warning because Corvert carries the risk of inducing a new, potentially fatal ventricular arrhythmia, such as Torsades de Pointes. Monitoring allows the healthcare team to immediately detect and intervene if a serious change in heart rhythm occurs, as required by regulatory warnings.

Q: What is the general success rate mentioned in studies for Corvert?

A: Clinical studies indicate that Corvert is often successful in converting atrial arrhythmias. Official information notes a conversion rate ranging from 30% to over 70% for atrial fibrillation and a generally higher rate (50% to over 80%) for atrial flutter. Research indicates the effectiveness tends to be greater when the abnormal rhythm is of recent onset.

Q: What should a patient do if they feel unwell after Corvert is given?

A: Since Corvert is administered in a hospital under continuous professional care, the patient’s healthcare provider or nurse should be informed immediately of any new or uncomfortable symptoms that occur. Important symptoms to report may include dizziness, lightheadedness, nausea, or any sudden change in how the heart feels, allowing the team to assess and respond quickly.

Q: Is Corvert the same as amiodarone, or are they different?

A: Corvert (ibutilide) and amiodarone are two distinct medications, though both are classified as Class III antiarrhythmic agents. Official documents restrict their use together because both drugs prolong the heart's QT interval, which can increase the risk of serious heart rhythm side effects when combined.

Q: Can Corvert be used for all types of irregular heartbeats?

A: No. Corvert is specifically indicated in regulatory documents for the rapid conversion of only two particular types of irregular heartbeats: atrial fibrillation and atrial flutter of recent onset. Its safety and effectiveness have not been established for other forms of irregular heart rhythm.

Q: Is Corvert generally used for short periods or long-term treatment?

A: Corvert is strictly intended for short-term, acute use. It is administered as a single, brief intravenous infusion, with a potential for only one repeat dose. It is not approved or intended for the chronic or long-term maintenance of a normal heart rhythm.

Q: What is the risk of a serious side effect with Corvert?

A: The most serious side effect is the potential to induce a new, dangerous heart rhythm, called Torsades de Pointes (TdP). Clinical trial data indicates that this serious proarrhythmic event occurred in approximately 4% to 7% of patients. This risk is managed by administering the drug under continuous heart monitoring with life-saving equipment readily available.

Q: Does Corvert affect the results of other heart tests?

A: Yes. Corvert is designed to significantly affect the heart's electrical system, causing a measurable prolongation of the QT interval on an electrocardiogram (ECG). This expected electrical change is what is continuously measured during the monitoring required for the drug's safe administration.

Q: What happens when Corvert leaves the body?

A: According to official product information, Corvert is primarily broken down (metabolized) in the liver by enzyme systems. The drug's components are generally eliminated from the body, primarily through the urine and partially through the feces.

Q: Can Corvert affect the liver?

A: Official information advises caution when using Corvert in patients with severe hepatic (liver) impairment. While the drug is metabolized in the liver, there is no official warning that the medication commonly causes routine liver damage in patients without pre-existing severe impairment.

Q: Is there a Black Box Warning associated with Corvert?

A: Yes. The FDA-mandated Boxed Warning highlights the major safety risk that Corvert can cause new, potentially fatal ventricular arrhythmias, specifically Torsades de Pointes. This warning is the official regulatory reason why the drug is restricted to hospital use, administered by trained personnel, and requires continuous ECG monitoring.

Q: Do patients feel anything specific when Corvert is administered?

A: Patient sensation can vary. Official documents note that some patients may experience common non-cardiac effects such as a headache or nausea during or shortly after the infusion. The care team is present to address any sensations, and patients are typically instructed to notify their nurse if they feel dizzy, lightheaded, or sense any change in their heartbeat.

Q: Can Corvert be used in women who are pregnant or breastfeeding?

A: For pregnancy, regulatory documents classify use as restricted: the drug should only be administered if the expected benefit to the mother is determined to outweigh the potential risk to the fetus. For nursing mothers, official documents recommend that breastfeeding be discouraged because it is unknown whether the substance passes into human milk.

Q: Does Corvert carry a risk of allergic reaction?

A: Yes. A known hypersensitivity or allergy to ibutilide or any of the product's components is listed as a contraindication, meaning the drug should not be administered. Although rare, serious allergic reactions, including anaphylaxis, have been reported in post-marketing surveillance.

Q: Can Corvert cause dizziness or fatigue?

A: Official adverse reaction data documents dizziness as an uncommon side effect (occurring in less than 1% of patients). However, fatigue is not listed among the commonly or uncommonly reported adverse reactions directly attributed to the drug in clinical trials.

Q: Is Corvert used to prevent future episodes of irregular heartbeat?

A: No. Corvert's official indication is specifically for the rapid conversion of an existing abnormal heart rhythm (atrial fibrillation or flutter) back to a normal one. It is not approved or intended for the long-term prevention or prophylaxis of future irregular heartbeat episodes.

Q: Does Corvert interact with common pain relievers like ibuprofen or acetaminophen?

A: Official regulatory documents do not specifically list common over-the-counter pain relievers such as ibuprofen or acetaminophen as drugs that have a documented major interaction with Corvert. The major documented interaction concern for Corvert is with prescription medications that also prolong the heart's QT interval.

Q: Can Corvert be used in children or adolescents?

A: No. Regulatory documents clearly state that the safety and effectiveness of Corvert have not been established in pediatric patients (those under 18 years of age).

Q: Is it necessary to stop taking other medications before receiving Corvert?

A: Yes, for certain drugs. Official warnings state that Class I or other Class III antiarrhythmic agents that prolong the QT interval must not be given concomitantly with Corvert or administered within 4 hours post-infusion to reduce safety risks.

Q: What are the limitations of the clinical trials conducted for Corvert?

A: Clinical trials primarily focused on the drug's short-term effectiveness in the acute conversion of atrial fibrillation and flutter, especially those of recent onset. Because of the drug's acute use, trials do not provide long-term data on the drug's efficacy or safety for chronic rhythm maintenance.

Q: Does Corvert cause long-term side effects?

A: Corvert is an acute, short-acting medication given once or twice in a controlled hospital setting. The most serious side effects, such as Torsades de Pointes, are acute events that occur within hours of administration. It is not generally associated with causing long-term side effects after the patient has recovered from the acute treatment and monitoring period.

Q: What is the difference between an AFib and an AFlutter?

A: Both are irregular heart rhythms that Corvert is indicated to treat. Atrial Fibrillation (AFib) is characterized by chaotic and disorganized electrical signals, causing the upper chambers to quiver. Atrial Flutter (AFlutter) involves a more organized, but still very rapid, electrical circuit pattern in the upper chambers.

Q: What is the generic name for Corvert?

A: The generic name for the drug Corvert is ibutilide fumarate (or simply ibutilide). The product is also available from various manufacturers under this generic name.

Q: Are there different brand names for the drug Corvert?

A: Corvert is the trade name for the active substance ibutilide fumarate. The drug is also available under its generic name, ibutilide fumarate, from various manufacturers.

Q: How long has Corvert been approved and available for use?

A: Corvert (ibutilide fumarate) was first approved by the U.S. Food and Drug Administration (FDA) in 1996 for the rapid conversion of recent-onset atrial fibrillation and atrial flutter.

Q: Is it true that Corvert is only for specific types of atrial fibrillation?

A: Yes. Official indications state Corvert is specifically for the conversion of atrial fibrillation that is of recent onset. Clinical studies show it is less effective for patients with chronic or long-standing atrial fibrillation.

Q: What is the function of the main ingredient, ibutilide, in Corvert?

A: The main ingredient, ibutilide, works by influencing the heart's electrical system. According to official documents, it primarily works by blocking certain ion channels that prolong the heart's electrical recovery time. This prolongation helps interrupt the abnormal electrical circuits causing the arrhythmia.

Storage Requirements

Condition	Requirement
Temperature	Store undiluted vials at Controlled Room Temperature, 20 to 25 C (68 to 77 F). Permitted excursions are between 15 and 30 C.
Light Protection	Vials must be stored in the original carton until use to protect the contents from light.
Child Safety	The medicine must be kept out of the reach and sight of children.
After Dilution	Solutions mixed with approved diluents are stable for 24 hours at room temperature or up to 48 hours if refrigerated (2 to 8 C).

Disposal Instructions

Unused or expired Corvert Injection must be disposed of according to applicable local regulations for pharmaceutical waste. The U.S. FDA recommends using a drug take-back program when available. Corvert is not listed as a medication recommended for disposal by flushing down the toilet or sink.